RAPT Therapeutics (RAPT) Cash from Investing Activities (2020 - 2024)
Historic Cash from Investing Activities for Therapeutics (RAPT) over the last 5 years, with Q4 2024 value amounting to -$843000.0.
- Therapeutics' Cash from Investing Activities fell 10408.45% to -$843000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $52.7 million, marking a year-over-year decrease of 4938.97%. This contributed to the annual value of $52.7 million for FY2024, which is 4938.97% down from last year.
- Latest data reveals that Therapeutics reported Cash from Investing Activities of -$843000.0 as of Q4 2024, which was down 10408.45% from $18.4 million recorded in Q3 2024.
- In the past 5 years, Therapeutics' Cash from Investing Activities ranged from a high of $32.4 million in Q2 2023 and a low of -$63.7 million during Q2 2021
- Over the past 5 years, Therapeutics' median Cash from Investing Activities value was $6.7 million (recorded in 2020), while the average stood at -$2.9 million.
- In the last 5 years, Therapeutics' Cash from Investing Activities plummeted by 143716.98% in 2021 and then skyrocketed by 41016.45% in 2023.
- Quarter analysis of 5 years shows Therapeutics' Cash from Investing Activities stood at $15.5 million in 2020, then plummeted by 202.56% to -$15.9 million in 2021, then crashed by 159.69% to -$41.3 million in 2022, then surged by 150.01% to $20.6 million in 2023, then crashed by 104.08% to -$843000.0 in 2024.
- Its Cash from Investing Activities was -$843000.0 in Q4 2024, compared to $18.4 million in Q3 2024 and $19.2 million in Q2 2024.